/
ANL
$11.41+$1.41 (+14.10%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$644.0M
64M shares
52-week range
$0.88 – $17.25
64% from low
Exchange
NASDAQ
ADRC
Borrow rate
8.72%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-3.59
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $45.7M | $0 | $0 | $0 | $5.0M |
| Cost of revenue | $1.5M | $1.5M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$1.5M | −$1.5M | $45.7M | $0 | $0 | $0 | $5.0M |
| Gross margin | — | — | 100.0% | — | — | — | 100.0% |
| R&D | $13.3M | $19.0M | $42.1M | $54.5M | $58.2M | $44.9M | $32.8M |
| Operating income | −$19.1M | −$26.1M | −$8.6M | −$67.3M | −$72.6M | −$52.9M | −$35.7M |
| EBITDA | −$15.9M | −$60.1M | −$53.5M | −$56.3M | −$106.2M | −$48.1M | −$32.6M |
| Net income | −$17.8M | −$63.4M | −$56.7M | −$58.8M | −$109.2M | −$51.9M | −$35.5M |
| Net margin | — | — | -124.0% | — | — | — | -710.6% |
| EPS (diluted) | -2.10 | -7.62 | -6.66 | -6.93 | -15.42 | -4.89 | -3.33 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5M | $-0.30 | $-0.60–$-0.15 | 5 |
| 2027 | $100000 | $-0.37 | $-0.53–$-0.22 | 3 |
| 2028 | $11M | $-0.45 | $-0.45–$-0.45 | 1 |
| 2029 | $1M | $-0.67 | $-0.67–$-0.67 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.73
Price
$11.41
Implied downside
-94%
Peer comparison
Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
www.adlainortye.com- Employees
- 109
- IPO / List date
- Sep 29, 2023
Held by traders on TradeandTell
No one on the platform currently holds ANL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 66,000 | $456.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANL yet.
